Cleveland Clinic's 20th Annual ASH Review
2019 ASH Review on R/R DLBCL: For Frail Unfit Patients, Addition of Polatuzumab Vedotin to BR Is Tolerable and Improves ORR, CR, PFS and OS
By
Cleveland Clinic's 20th Annual ASH Review
FEATURING
Brian Hill
By
Cleveland Clinic's 20th Annual ASH Review
FEATURING
Brian Hill
Login to view comments.
Click here to Login